Dexcom Inc
DXCM Health Care · No analyses yet
Mentioned in recent filings: Tariffs
What changed
No articles about this company yet. Follow it to hear when the first one appears.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
| Company | Latest revenue | Revenue YoY | Operating margin |
|---|---|---|---|
| Dexcom Inc DXCM | — | — | — |
| Unitedhealth Group Inc UNH | $113B | -0.4% | 5.8% |
| Mckesson Corp MCK | $111B | +7.6% | 1.4% |
| CVS Health Corp CVS | $108B | +5.4% | 3.3% |
| Cigna Group CI | $73.7B | +5.6% | 3.3% |
| Cardinal Health Inc CAH | $67.5B | +5.5% | 1.1% |
| Elevance Health, Inc. ELV | $51.4B | +1.4% | 2.5% |
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|---|---|
| September 14, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|---|---|---|---|
| BlackRock | 38,244,137 | $2,575,742,626 | -1.8% | Q2 2026 |
| State Street | 18,380,806 | $1,237,947,284 | +2.5% | Q2 2026 |
| Geode Capital Management | 12,426,515 | $834,165,910 | +0.6% | Q2 2026 |
| Wellington Management | 8,527,471 | $574,325,172 | -8.6% | Q2 2026 |
| Norges Bank (Norway's sovereign fund) | 6,868,090 | $462,565,862 | — | Q2 2026 |
| Fidelity (FMR) | 1,893,246 | $127,510,091 | +13.2% | Q2 2026 |
| Renaissance Technologies | 1,630,796 | $109,834,111 | +3.0% | Q2 2026 |
| Citadel Advisors | 1,211,767 | $81,612,507 | -42.1% | Q2 2026 |
| Bridgewater Associates | 400,929 | $27,002,568 | +187.0% | Q2 2026 |
| Millennium Management | 395,392 | $26,629,651 | -75.6% | Q2 2026 |
| Two Sigma Investments | 46,697 | $3,145,043 | -95.8% | Q2 2026 |
| D. E. Shaw & Co. | 5,679 | $382,481 | -79.5% | Q2 2026 |
| T. Rowe Price | 2,238,713 | $150,778 | +54.9% | Q2 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.
